Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 702

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 702
---
 information with respect to the beneficial ownership of the common stock of the combined company upon consummation of the Merger, assuming the closing of the Merger occurred on January 15, 2025, by: (i) each person or group of affiliated persons known by Cara or Tvardi to become the beneficial owner of more than 5% of the common stock of the combined company upon the closing of the Merger; (ii) each of the directors of the combined company; (iii) each of the executive officers of the combined company; and (iv) all executive officers and directors of the combined company as a group. Unless otherwise indicated in the footnotes to this table, Cara and Tvardi believe that each of the persons named in this table have sole voting and investment power with respect to the shares indicated as beneficially owned. The following table assumes (i) no exercise of outstanding options or warrants to purchase shares of Cara common stock or Tvardi common stock prior to the closing of the Merger, (ii) an Exchange Ratio of 0.2042, (iii) a number of shares issued in connection with the merger equal to 11,878,447 (including 1,921,436 Conversion Shares), (iv) the closing of the Merger and (v) a Reverse Stock Split of 1-for-2, to be implemented immediately prior to the closing of the Merger. Based on these assumptions, there will be a total of 14,204,018 shares of combined company common stock outstanding upon the closing of the Merger. Shares of the combined company’s common stock that may be acquired by an individual or group within 60 days of January 15, 2025, pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of the combined company’s common stock of any other person shown in the table. Unless otherwise indicated, the address for the following stockholders is: c/o Cara Therapeutics, Inc., 400 Atlantic Street, Suite 500, Stamford, CT 06901.

| Name of Beneficial Owner                                        | ​ | ​ | Number of SharesBeneficially Owned |   |           |   | ​ | ​ | Percentage of SharesBeneficially Owned |   |        |   | ​ |
| 5% or Greater Stockholders                                      | ​ | ​ | ​                                  | ​